Keytruda 100 MG/4 ML vial 4ML
Ended Awarded Last action
- Contract number
- SPE2DR26FDJJ4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $26,237
Award facts
- Contract value 100% obligated
- $26,236.77 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $26,236.77 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Keytruda (pembrolizumab) 100 mg/4 mL vials. The award, made on December 29, 2025, with an ultimate completion date of January 21, 2026, utilizes firm fixed-price pricing with no set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy that authorizes DLA to procure a comprehensive range of pharmaceuticals and medical consumables to support Department of Defense healthcare operations globally.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal military medical supply chain, with substantial contracting activity demonstrating consistent performance across multiple therapeutic categories including oncology treatments, biologics, vaccines, and specialty pharmaceuticals. The company's expanded role as a prime vendor contractor under the PPV-G GEN V program, which features a $499.999 billion ceiling and extends through December 31, 2036, positions it to fulfill the diverse and specialized pharmaceutical requirements of military healthcare facilities worldwide. The vendor maintains established performance standards across numerous delivery orders and demonstrates no identified subcontractor relationships in its federal contracting activities.
Quick answers
Who was awarded contract SPE2DR26FDJJ4?
SPE2DR26FDJJ4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 29, 2025.
How much is contract SPE2DR26FDJJ4 worth?
The government has obligated $26,237 on SPE2DR26FDJJ4.
Is contract SPE2DR26FDJJ4 an order under another contract?
Yes. SPE2DR26FDJJ4 is a delivery order under SPE2DR25D9144, an indefinite delivery contract.
Was contract SPE2DR26FDJJ4 competed?
The extent of competition for SPE2DR26FDJJ4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award